Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Genelux CorporationNASDAQ: GNLX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization turns negative

Q1 FY2026 depreciation & amortization was -$61K, compared with $139K a year earlier. Trailing-twelve-month depreciation & amortization was $44K. Over 3 fiscal years it compounded at -36.8% a year.

Context

  • Depreciation & amortization amounted to 3050.0% of revenue in FY2025, down 8237.5 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near -$61K or moves back toward the trailing-twelve-month quarterly average of $11K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$61K-145.2% QoQ
Last fiscal yearDec 2025
$244K-73.0% YoY
LTMMar 2026
$44K+116.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-143.9%——
1 year-73.0%——
3-year CAGR-36.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
244K USD
Year-over-year change
-73.0%
4-year CAGR
-27.7%

Depreciation & Amortization vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +116.9% is the highest of 9, against a peer median of +0.7%.
  • Depreciation & amortization amounts to 550.0% of revenue for GNLX, versus a peer median of 96.0%.
GNLX Competitors
Depreciation & Amortization for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+3.0%28.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-11.2%33645.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 2.5M CHF+15.5%+0.4%69.9%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$1.99M USD-1.7%-30.8%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$1.23M USD—+8.0%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.18M USD+9.0%-11.2%236.0%
SLNSilence Therapeutics plcLTM Mar 2026$885K USD—-2.3%96.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$749K USD-23.9%+2.8%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K USD+19.3%-0.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
GNLXGenelux CorporationLTM Mar 2026$44K USD+116.9%-36.8%550.0%
Peer median (excluding GNLX) —+0.7%-0.7%96.0%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.38M)(5.21M)(28.3M)(29.87M)(32.15M)
Depreciation & Amortization895K968K1.02M903K244K
Deferred Income Tax348K0000
Stock-Based Compensation4.27M2.42M5.2M6.07M5.87M
Change in Working Capital4.08M(1.69M)(3.28M)751K(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables754K2.31M(2.36M)2.16M(1.21M)
Other Working Capital3.33M(4M)(923K)(1.41M)167K
Other Non-Cash Items196K(56K)5.08M917K1.81M
Operating Cash Flow(6.59M)(3.57M)(20.28M)(21.23M)(25.27M)
Capital Expenditures0(49K)(1.03M)(381K)(1.1M)
Acquisitions (Net)00000
Purchases of Investments00(13.7M)(29M)(18.26M)
Sales of Investments00021.25M31.5M
Other Investing Activities00000
Investing Cash Flow0(49K)(14.72M)(8.13M)12.14M
Debt Repayment(558K)970K215K00
Common Stock Issued143K120K39.65M27.82M9.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities145K(1.45M)4.16M688K0
Financing Cash Flow(270K)(478K)44.02M28.51M9.9M
Effect of Forex Changes00000
Net Change in Cash(6.86M)(4.1M)9.02M(853K)(3.23M)
Free Cash Flow(6.59M)(3.62M)(21.3M)(21.61M)(26.37M)

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.